Novosanis receives VLAIO grant of €250.000

You are here

Press Release

Novosanis receives VLAIO grant of € 250.000

Wijnegem, Belgium, June 21st 2016: Flanders Innovation & Entrepreneurship (VLAIO) today announced that it granted € 250.000 for research and development of LYO-ID, a user & patient friendly highly accurate intradermal injection device suited for freeze-dried medicinal products.

Novosanis has initiated the development of LYO-ID, a device based on the proprietary VAX-ID™ device. The LYO-ID device is suited for improving intradermal injection of freeze-dried medicinal products, such as vaccines. From technological point of view, the device will have a unique architecture comprising two chambers that can be interconnected allowing small volumes of both powder and liquid to mix prior to injection. Like VAX-ID™, also LYO-ID will allow for highly accurate intradermal injections. Combined with its ease of use, LYO-ID will de-risks currently error-prone intradermal injections. Additionally, freeze-dried vaccines can be stored and shipped at ambient temperature thereby saving on costs of cold chain.

Koen Beyers, Chief Technology Officer at Novosanis explains: “Novosanis is proud to have been granted this subsidy by VLAIO. This allows us to strengthen our position as an innovator in the field of medical devices for treatment and prevention of infectious diseases and oncology. It will also allow Novosanis to further expand its R&D team and contribute in strengthening the position of Flanders in MedTech and Biotech.”

ENDS

For more information, please contact:

Julie Post, Communication Manager Novosanis
+32 3 485 50 16
press@novosanis.com

About Novosanis

Novosanis is an innovative developer and producer of medical devices adding value to the accuracy of diagnostics tests, vaccination based actions and the overall patient’s comfort.

We are a medical device company active in the field of infectious diseases and oncology in the areas of prevention, detection and treatment.

Novosanis prospers in user-friendly and smart medical devices meeting all regulatory and quality requirements, solutions that can improve the accuracy of the diagnostic test while making the handling easier, more consistent and more comfortable for the person.

Currently we have two device platforms in portfolio: VAX-ID™, suited for accurate intradermal injections and Colli-Pee™, suited for standardized collection of first void urine. Colli-Pee™ is in commercial stage and is CE marked.

About VAX-ID™:  please visit: http://www.novosanis.com/devices/vax-id